Stemline Therapeutics (NASDAQ:STML) Lifted to Buy at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Stemline Therapeutics (NASDAQ:STML) from a hold rating to a buy rating in a research report report published on Saturday, BidAskClub reports.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright set a $35.00 price target on shares of Stemline Therapeutics and gave the company a buy rating in a research report on Thursday, June 20th. Roth Capital reaffirmed a buy rating on shares of Stemline Therapeutics in a research report on Thursday, May 23rd. ValuEngine raised shares of Stemline Therapeutics from a hold rating to a buy rating in a research report on Thursday, March 21st. Piper Jaffray Companies set a $23.00 price objective on shares of Stemline Therapeutics and gave the stock a buy rating in a research report on Monday, March 18th. Finally, Zacks Investment Research raised shares of Stemline Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 5th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $25.20.

Stemline Therapeutics stock opened at $14.74 on Friday. Stemline Therapeutics has a fifty-two week low of $7.82 and a fifty-two week high of $18.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.07 and a quick ratio of 5.03. The firm has a 50 day moving average of $14.63. The firm has a market cap of $695.46 million, a P/E ratio of -4.93 and a beta of 1.25.

Stemline Therapeutics (NASDAQ:STML) last posted its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The company had revenue of $5.05 million for the quarter, compared to analysts’ expectations of $2.61 million. As a group, research analysts predict that Stemline Therapeutics will post -2.14 earnings per share for the current year.

In related news, COO Kenneth Hoberman sold 25,817 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $14.27, for a total value of $368,408.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.10% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stemline Therapeutics in the first quarter valued at $36,000. Great West Life Assurance Co. Can acquired a new position in Stemline Therapeutics in the fourth quarter valued at $47,000. Legal & General Group Plc increased its stake in Stemline Therapeutics by 27.1% in the fourth quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 1,120 shares during the period. BNP Paribas Arbitrage SA acquired a new position in Stemline Therapeutics in the first quarter valued at $102,000. Finally, Metropolitan Life Insurance Co. NY increased its stake in Stemline Therapeutics by 327.0% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 6,527 shares during the period. 77.66% of the stock is owned by hedge funds and other institutional investors.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

See Also: What does RSI mean?

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Equities Research Analysts’ Price Target Changes for July, 17th
Equities Research Analysts’ Price Target Changes for July, 17th
Trupanion Inc  Receives Average Recommendation of “Buy” from Analysts
Trupanion Inc Receives Average Recommendation of “Buy” from Analysts
MorphoSys AG  Receives Average Rating of “Hold” from Brokerages
MorphoSys AG Receives Average Rating of “Hold” from Brokerages
Brokerages Anticipate Calix Inc  Will Post Quarterly Sales of $99.95 Million
Brokerages Anticipate Calix Inc Will Post Quarterly Sales of $99.95 Million
Primas  Price Tops $0.0906
Primas Price Tops $0.0906
iShares S&P Mid-Cap 400 Growth ETF   Shares Down 0.2%
iShares S&P Mid-Cap 400 Growth ETF Shares Down 0.2%


 
© 2006-2019 Zolmax.